Artal Group S.A. Metacrine, Inc. Transaction History

Artal Group S.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2020 Feb 11, 2021	SELL	$7.75 - $11.42 $2.98 Million - $4.39 Million	-384,615 Reduced 29.37%	924,898 $7.27 Million
Q3 2020 Nov 13, 2020	BUY	$9.38 - $11.76 $12.3 Million - $15.4 Million	1,309,513 New	1,309,513 $13.4 Million

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.